In a study including 251 RCC patients treated with sunitinib, high pre-therapeutic Ang2 expression, and more strongly, combined high expression of both Ang2 and CD31, were associated with a high clinical benefit rate, but not with PFS or OS [110]. The gene discussed is ANGPT2; the disease is renal cell carcinoma.